Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 avr. 2021 01h30 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces First Peer-Reviewed Publication in "Science Advances" on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation

NANTES, France, April 06, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the first peer-reviewed publication on OSE-230, a novel and innovative approach...
01 avr. 2021 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope* responses.CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and...
26 mars 2021 13h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update

Major expansion of clinical portfolio including initiation of clinical trials with Tedopi® in ovarian cancer, OSE-127/S95011 in ulcerative colitis, FR104 in renal transplant and an upcoming phase 1/2...
15 mars 2021 01h30 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,...
11 mars 2021 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting

CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation.BiCKI®-IL-7, bifunctional therapy targeting PD-1 and IL-7 to...
23 févr. 2021 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference

NANTES, France, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of...
17 févr. 2021 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011

NANTES, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that it has strengthened intellectual property rights for its...
15 févr. 2021 01h30 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high unmet medical needs,Divided into three tranches including...
28 janv. 2021 12h00 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development...
25 janv. 2021 01h30 HE | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011

Milestone as part of the collaborative program named EFFIMab marks continued clinical progressInterleukin-7 receptor antagonist (IL-7R) OSE-127/S95011 is currently in a Phase 2 clinical trial in...

Page précédente